Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
24.70
-0.57 (-2.26%)
At close: Mar 26, 2026, 4:00 PM EDT
24.70
0.00 (0.00%)
After-hours: Mar 26, 2026, 5:30 PM EDT
Castle Biosciences Employees
Castle Biosciences had 883 employees as of December 31, 2025. The number of employees increased by 122 or 16.03% compared to the previous year.
Employees
883
Change
122
Growth
16.03%
Revenue / Employee
$389,840
Profits / Employee
-$27,359
Market Cap
734.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 883 | 122 | 16.03% | 883 | 0 |
| Sep 30, 2025 | 823 | 113 | 15.92% | 823 | 0 |
| Jun 30, 2025 | 798 | 95 | 13.51% | 798 | 0 |
| Mar 31, 2025 | 784 | 146 | 22.88% | 784 | 0 |
| Dec 31, 2024 | 761 | 151 | 24.75% | 761 | 0 |
| Sep 30, 2024 | 710 | 123 | 20.95% | 710 | 0 |
| Jun 30, 2024 | 703 | 121 | 20.79% | 703 | 0 |
| Mar 31, 2024 | 638 | 95 | 17.50% | 638 | 0 |
| Dec 31, 2023 | 610 | 67 | 12.34% | 610 | 0 |
| Sep 30, 2023 | 587 | 70 | 13.54% | 587 | 0 |
| Jun 30, 2023 | 582 | 100 | 20.75% | 582 | 0 |
| Dec 31, 2022 | 543 | 198 | 57.39% | 542 | 1 |
| Sep 30, 2022 | 517 | 206 | 66.24% | 517 | 0 |
| Jun 30, 2022 | 482 | 190 | 65.07% | 482 | 0 |
| Dec 31, 2021 | 345 | 144 | 71.64% | 342 | 3 |
| Sep 30, 2021 | 311 | 110 | 54.73% | 311 | 0 |
| Jun 30, 2021 | 292 | - | - | 292 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| NeoGenomics | 2,500 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| GeneDx Holdings | 1,300 |
| GRAIL | 910 |
| CareDx | 765 |
| Veracyte | 755 |
CSTL News
- 2 days ago - Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript - Seeking Alpha
- 13 days ago - Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB - GlobeNewsWire
- 17 days ago - DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk - GlobeNewsWire
- 22 days ago - Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB - GlobeNewsWire
- 23 days ago - Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas - GlobeNewsWire
- 27 days ago - Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results - GlobeNewsWire
- 5 weeks ago - Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis - GlobeNewsWire